U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07554495) titled 'Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents' on April 15.
Brief Summary: This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Polyarticular Course Juvenile Idiopathic Arthritis
Intervention:
DRUG: Filgotinib
IP will be provided as commercially developed film-coated tablets or age-appropriate film- coated tablets for use in pa...